Genome-wide Association Study of Survival in Early-stage Non-Small Cell Lung Cancer

Shaowen Tang(Nanjing Medical University), Hongbing Shen(Jiangsu Cancer Hospital), Guangfu Jin(Nanjing Health and Health Commission), Juncheng Dai(Nanjing Medical University), Lingmin Hu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaping Chen(Capital Medical University), Yongqian Shu(Jiangsu Province Hospital), Minjie Chu(Nantong University), Zhibin Hu(Nanjing Medical University), Yi Wang(Anhui University of Traditional Chinese Medicine), Lin Xu(Guangdong Pharmaceutical University), Yun Pan(University of Science and Technology of China), Songyu Cao(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongxia Ma(Wuhan Prevention and Treatment Center for Occupational Diseases)
Annals of Surgical Oncology
August 21, 2014
10.1245/s10434-014-3983-0
Cited by 51

Related Papers

Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
|Nature Genetics|2017|804
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1
|Cancer Research|2016|486
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475